This proof-of-concept study reported an association between serum NfL and GFAP levels measured early in the course of MS and subsequent EDSS progression, showing acceptable predictive power to differentiate two groups of benign and aggressive forms of RRMS in patients with a disease duration of 20 years and an average follow-up period of approximately 18 years. This evidence concerns the gene NEFL and myeloid sarcoma.